克隆体在小鼠体内的分布。

Cancer treatment reports Pub Date : 1987-12-01
P E Noker, D L Hill
{"title":"克隆体在小鼠体内的分布。","authors":"P E Noker,&nbsp;D L Hill","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The distribution of the novel alkylating agent clomesone [2-chloroethyl (methylsulfonyl)-methane sulfonate] has been studied in mice after iv administration of 35 mg/kg. In plasma, [14C]clomesone was eliminated in an apparent single phase with a half-life of 11 minutes. The elimination of total radioactivity occurred with an initial half-life of 51 minutes, and then in prolonged phase of undetermined length. At least two organic soluble metabolites were detectable in plasma. Highest tissue concentrations of radioactivity were in liver, kidney, and small intestines where, at most times of analysis, the levels were two to three times higher than those in plasma. The rate of elimination of radiolabel from spleen, lungs, brain, and muscle, which contained about equal concentrations of radioactivity at most times after dosing, paralleled the rate of loss from plasma. A major proportion of the radioactivity in tissues was bound to trichloracetic acid-precipitable macromolecules. Within 24 hours, 77.6% of the dose was recovered in urine. High-pressure liquid chromatographic analyses of 8-hour urine collections demonstrated that less than 2% of the dose was excreted unchanged. These results demonstrate that clomesone is rapidly eliminated from plasma and that it and/or its products become extensively bound to tissue components.</p>","PeriodicalId":9581,"journal":{"name":"Cancer treatment reports","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Distribution of clomesone in mice.\",\"authors\":\"P E Noker,&nbsp;D L Hill\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The distribution of the novel alkylating agent clomesone [2-chloroethyl (methylsulfonyl)-methane sulfonate] has been studied in mice after iv administration of 35 mg/kg. In plasma, [14C]clomesone was eliminated in an apparent single phase with a half-life of 11 minutes. The elimination of total radioactivity occurred with an initial half-life of 51 minutes, and then in prolonged phase of undetermined length. At least two organic soluble metabolites were detectable in plasma. Highest tissue concentrations of radioactivity were in liver, kidney, and small intestines where, at most times of analysis, the levels were two to three times higher than those in plasma. The rate of elimination of radiolabel from spleen, lungs, brain, and muscle, which contained about equal concentrations of radioactivity at most times after dosing, paralleled the rate of loss from plasma. A major proportion of the radioactivity in tissues was bound to trichloracetic acid-precipitable macromolecules. Within 24 hours, 77.6% of the dose was recovered in urine. High-pressure liquid chromatographic analyses of 8-hour urine collections demonstrated that less than 2% of the dose was excreted unchanged. These results demonstrate that clomesone is rapidly eliminated from plasma and that it and/or its products become extensively bound to tissue components.</p>\",\"PeriodicalId\":9581,\"journal\":{\"name\":\"Cancer treatment reports\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1987-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer treatment reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment reports","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

研究了新型烷基化剂氯美松[2-氯乙基(甲基磺酰基)-甲烷磺酸盐]在小鼠体内静脉给药35 mg/kg后的分布。在血浆中,[14C]克隆体在明显的单相中被消除,半衰期为11分钟。总放射性的消除发生在最初的半衰期为51分钟,然后是一个不确定长度的延长阶段。血浆中至少检出两种有机可溶性代谢物。肝脏、肾脏和小肠的组织放射性浓度最高,在大多数分析中,这些组织的放射性水平是血浆的两到三倍。脾、肺、脑和肌肉在给药后大部分时间的放射性浓度大致相等,其放射性标签的消除率与血浆的损失率相当。组织中的大部分放射性与三氯乙酸可沉淀的大分子结合。24小时内,77.6%的剂量从尿中回收。高压液相色谱分析8小时收集的尿液表明,只有不到2%的剂量不变地排出体外。这些结果表明,克隆体从血浆中迅速消除,它和/或它的产物广泛结合到组织成分。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Distribution of clomesone in mice.

The distribution of the novel alkylating agent clomesone [2-chloroethyl (methylsulfonyl)-methane sulfonate] has been studied in mice after iv administration of 35 mg/kg. In plasma, [14C]clomesone was eliminated in an apparent single phase with a half-life of 11 minutes. The elimination of total radioactivity occurred with an initial half-life of 51 minutes, and then in prolonged phase of undetermined length. At least two organic soluble metabolites were detectable in plasma. Highest tissue concentrations of radioactivity were in liver, kidney, and small intestines where, at most times of analysis, the levels were two to three times higher than those in plasma. The rate of elimination of radiolabel from spleen, lungs, brain, and muscle, which contained about equal concentrations of radioactivity at most times after dosing, paralleled the rate of loss from plasma. A major proportion of the radioactivity in tissues was bound to trichloracetic acid-precipitable macromolecules. Within 24 hours, 77.6% of the dose was recovered in urine. High-pressure liquid chromatographic analyses of 8-hour urine collections demonstrated that less than 2% of the dose was excreted unchanged. These results demonstrate that clomesone is rapidly eliminated from plasma and that it and/or its products become extensively bound to tissue components.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group. Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Phase II trial of fludarabine phosphate in patients with head and neck cancer: a Southwest Oncology Group Study. Phase II study of fludarabine phosphate in previously untreated patients with colorectal carcinoma: a Southwest Oncology Group Study. Identification of new drugs in small cell lung cancer: phase II agents first?
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1